US 12,065,488 B2
Anti-IL-6 antibody
Yan Chen, Malvern, PA (US); Debra Gardner, Bear, DE (US); David M. Knight, Berwyn, PA (US); Michael W. Lark, Devon, PA (US); Bailin Liang, Jacksonville, FL (US); David M. Marquis, Encinitas, CA (US); David J. Shealy, Downingtown, PA (US); Eric Michael Smith, San Diego, CA (US); Xiao-yu R. Song, Bridgewater, NJ (US); Vedrana Stojanovic-Susulic, Princeton Junction, NJ (US); Raymond Sweet, Bryn Mawr, PA (US); Susan Tam, Boothwyn, PA (US); Alain P. Vasserot, Carlsbad, CA (US); Sheng-Jiun Wu, Ambler, PA (US); and Jing Yang, Ambler, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US); and Applied Molecular Evolution, Inc., San Diego, CA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US); and Applied Molecular Evolution, Inc., San Diego, CA (US)
Filed on Nov. 1, 2021, as Appl. No. 17/516,082.
Application 17/516,082 is a division of application No. 16/717,594, filed on Dec. 17, 2019, granted, now 11,180,549.
Application 15/461,886 is a division of application No. 15/132,851, filed on Apr. 19, 2016, granted, now 9,631,016.
Application 15/132,851 is a division of application No. 14/096,596, filed on Dec. 4, 2013, granted, now 9,340,613.
Application 14/096,596 is a division of application No. 13/524,684, filed on Jun. 15, 2012, granted, now 8,623,362.
Application 13/524,684 is a division of application No. 13/283,177, filed on Oct. 27, 2011, granted, now 8,226,611.
Application 13/283,177 is a division of application No. 12/901,200, filed on Oct. 8, 2010, granted, now 8,067,003.
Application 12/901,200 is a division of application No. 12/470,753, filed on May 22, 2009, granted, now 7,833,755.
Application 12/470,753 is a division of application No. 11/413,561, filed on Apr. 28, 2006, granted, now 7,560,112.
Application 16/717,594 is a continuation of application No. 15/461,886, filed on Mar. 17, 2017, abandoned.
Prior Publication US 2022/0048985 A1, Feb. 17, 2022
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/248 (2013.01) [A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 4 Claims
 
1. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-6 antibody comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:132 comprising the sequence S-X1-X2-X3-X4-V-X5-Y-M-Y, wherein X1 is A or G, X2 is S or R, X3 is H, I, S, or Y, X4 is S or Y, and X5 is S or F;
a CDRL2 amino acid sequence of SEQ ID NO:133 comprising the sequence D-X6-S-X7-L-X8-S, wherein X6 is F, L, M, or T, X7 is N or E, and X8 is A or T; and
a CDRL3 amino acid sequence of SEQ ID NO:134 comprising the sequence X9-X10-W-S-G-Y-P-Y-T, wherein X9 is M, C, or S, and X10 is Q or C;
said heavy chain variable region comprising:
a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:135 comprising the sequence G-F-X11-X12-S-X13-F-A-X14-S, wherein X11 is T or Q, X12 is F, S, or T, X13 is S or P, and X14 is L or M;
a CDRH2 amino acid sequence of SEQ ID NO:136 comprising the sequence K-X15-S-X16-G-G-S-X17-X18-Y-X19-X20-D-T-X21-X22-X23, wherein X15 is A or I, X16 is S or P, X17 is Y or W, X18 is T, E, or Y, X19 is Y or F, X20 is P, S, D, or F, X21 is V or D, X22 is T or A, and X23 is G or P; and
a CDRH3 amino acid sequence of SEQ ID NO:137 comprising the sequence Q-L-W-G-X24-Y-A-L-D-X25, wherein X24 is S, Y, T, or N, and X25 is Y, T, F, or I.